BG45 - HDAC3 Inhibitor. CAS# 926259-99-6 Catalog No.:M60266-10S InChi: InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14

InChi: InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14

4-b]indole

This inhibition of MEK1/2 is noncompetitive with ERK and ATP

is a cell-permeable Stat3 inhibitor that binds to the Stat3-SH2 domain

is a potent and selective histone deacetylase HDAC4 and HDAC5 inhibitor (IC50 ~11

BG45 - HDAC3 Inhibitor. CAS# 926259-99-6 Catalog No.:M60266-10S InChi: InChI=1S/C26H23F2N3O4/c1-14(29-25(34)23(32)15-11-16(27)13-17(28)12-15)24(33)30-22-20-9-4-3-7-18(20)19-8-5-6-10-21(19)31(2)26(22)35/h3-14BG45, CAS No. 926259 99 6, is a potent, selective and cell permeable HDAC3 inhibitor. It inhibits HDAC3 with IC50 of 289 nM. It has IC50 of 2. 0 M, 2. 2 M and >20 M for HDAC1, HDAC2, and HDAC6 in cell free assays, respectively. BG45 triggers significant MM cell growth inhibition via apoptosis, evidenced by caspase and poly (ADP ribose) polymerase cleavage. BG45 alone and in combination with bortezomib triggers significant tumor growth inhibition in